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bstract
We have developed a web-based user-interface (web interface) to enhance the usefulness of health-economic evaluations to support decision
aking (http://pcv.healtheconomics.nl). It allows the user to interact with a health-economic model to evaluate predefined and customized
cenarios and perform sensitivity analysis. To explore its usefulness, it was applied to an evaluation of cost-effectiveness of nation-wide infant
accination with the 7-valent pneumococcal conjugate vaccine (PCV7), that was used to support a policy decision on the inclusion of PCV7 in
he national vaccination program (NVP) of the Netherlands. We used a decision-tree analytic model to project the impact of infant vaccination
ith four doses of PCV7 on an annual cohort of infants born in the Netherlands. The base-case analysis includes the beneficial effects on
nvaccinated individuals (herd protection). Additional scenarios varying the number of doses, discount rate for effects and the number of
erotypes in the vaccine were evaluated and can be analysed on the web. Our model projects a base-case incremental cost-effectiveness ratio
iCER) of D 14,000 (95% uncertainty interval (UI): 9,800–20,200) per quality adjusted life year (QALY) or D 15,600 (95% UI: 11,100–23,900)
er life year gained (LYG).




ceywords: Pneumococcal conjugate vaccine PCV; Web interface for policy
. Introduction
Decision makers in various countries increasingly use eco-
omic evaluation to support decisions on the inclusion of new
accines in their NVPs. For example, Welte et al. recently
∗ Corresponding author at: Social Pharmacy, Pharmacoepidemiology &
harmacotherapy, University of Groningen, The Netherlands, Antonius
eusinglaan 1, 9713 AV Groningen, The Netherlands.
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resented an overview on the role of health-economics in
ecision making concerning the introduction of meningo-
occal group C conjugate vaccines in NVPs [1]. The type
f analysis underlying such economic evaluation generally
mploys some form of modeling to simulate the costs and
ffects of a vaccination program. In this study we focus
n further enhancing the flexibility of applying such mod-
ls and the transparency of their results. Our approach aims
o increase the applicability of these evaluations to support
olicy decisions by providing a web interface for economic
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redefined and customized scenarios. In addition, it allows
he user to perform sensitivity analysis and generate various
raphs, such as cost-effectiveness acceptability curves and
catter plots. By observing the impact of changes in model
arameters, the user is provided with additional insights into
he model, its limitations and the intrinsic uncertainty of the
odel outcome.
As an illustration we will present the results of a study
hat has recently been used to support a recommendation
f the Health Council to the Ministry of Health on nation-
ide vaccination of infants with PCV7 (Prevnar®/Prevenar®,
yeth) in the Netherlands. In particular, inclusion of
CV7 against Streptococcus pneumoniae in the NVP of
he Netherlands was recommended (and is now imple-
ented), also based on our cost-effectiveness estimates
2].
Pneumococcal infections in infants present an important
ause of invasive disease such as meningitis and bacteremia,
nd non-invasive disease such as pneumonia and otitis media.
nvasive Pneumococcal Disease (IPD) is associated with high
ortality rates [3,4] and may cause severe lifelong com-
lications [5,6]. Non-invasive pneumococcal disease causes
high burden to society due to the high incidence of
nfection-related disease, such as otitis media and pneu-
onia. In Western Europe, it is estimated that every child
xperiences one or more episodes of otitis media before the
ge of 2 years [7,8]. A number of studies have assessed
he potential economical impact of mass infant vaccina-
ion with PCV7 (Prevnar; Wyeth) [9–12], since the first
ublished clinical trial showed the high efficacy of this
accine in the prevention of IPD [13] (see also McIntosh
14] for a recent review). Additionally, ongoing research
as provided important new data. For example, recent evi-
ence indicates that with less than four doses of the vaccine
sufficient level of immunological protection might also
e attained [15]. Also, protective effects of infant vacci-
ation on unvaccinated age groups (herd protection), have
een reported by Whitney et al. [16]. In a health-economic
nalysis, Melegaro and Edmunds have shown a very sub-
tantial effect of the inclusion of herd protection on the
CER in England and Wales, reducing it more than 10 fold
12].
For the Netherlands an economic evaluation was pub-
ished previously by Bos et al. based on research during
000–2001 [17]. Their model estimated the impact and cost-
ffectiveness of nation-wide infant vaccination with PCV7
t the age of 2, 3, 4 and 12 months. In this paper we
resent the updated results obtained with this model with
ecent epidemiological and cost data, including the effects of
erd protection, alternative dosage schedules and alternative
olyvalent vaccines. All presented scenario- and sensitiv-
ty analyses were performed with the web interface that is
ublicly accessible at http://pcv.healtheconomics.nl. In the
iscussion, we will further address the role web-based inter-








In this section we present a brief description of the orig-
nal study by Bos et al. [17] that was used as the basis for
his evaluation. It was updated to include recent epidemi-
logic data and health care unit costs. Bos et al. used a
ecision-tree analytic model to project the impact of infant
accination with four doses of PCV7 on the incidence of
neumococcal infections in infants and children up to and
ncluding 9 years of age from a societal perspective. The
ost per dose of vaccination including administration costs
as assumed to be D 45.20. The decision tree differenti-
ted between the complications of meningitis, bacteremia,
neumonia and otitis media. Lifetime costs, financial bene-
ts and health gains were estimated for an annual cohort of
200,000 infants (source: Central Bureau of Statistics) born
n the Netherlands in 2001. Both health effects and costs
ere discounted at a rate of 4%. The analytic time frame
f the study was 10 years, corresponding to the assumed
eriod of protection of the vaccine. To assess the poten-
ial serotype coverage of the vaccine against disease-causing
erotypes and the incidence of IPD (pneumococcal meningi-
is and pneumococcal bacteremia) data from the Netherlands
eference Laboratory for Bacterial Meningitis (NRBM) for
he years 1996–2001 was used [18]. The age specific inci-
ences of pneumonia and otitis media were estimated using
ata from the Integrated Primary Care Information Project
IPCI) [19] for the years 1997–2000. The length of hospi-
al stay (LOS) was estimated using data from PRISMANT
ealth Care for the years 1996–2001 [20]. QALYs and cor-
esponding losses in quality of life due to neurological and
hysical sequelae, hearing impairments and invasive pneu-
onia was considered using EuroQol assessments. An in
epth description of the model can be found in the original
aper [17].
.2. Updating the model
In particular, the average number of cases of IPD per year
as updated with data on the years 2001–2004 from the
etherlands Reference Laboratory for Bacterial Meningitis
NRBM) [21]. This data is shown in Table 1, corrected for
nderreporting (the percentages of reported bacteremia and
eningitis cases in the Netherlands were assumed to be 40%
nd 80%, respectively [22]).
Also shown in Table 1, are the average number of cases
f pneumonia and the average number of episodes of otitis
edia per year in the Netherlands as derived from the IPCI
atabase (based on general practitioner (GP) patient records),
rrespective of causative agent [19]. The number of episodes
f otitis media was adjusted to account for the percentage of
egistered cases in the IPCI database (cases treated by a GP),
ssumed to be 30% [23]. Tables 2 and 3 show the clinical
nd resource use parameters used in the model. Unit costs
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Table 1
The average number of cases per year in the Netherlands of pneumococcal meningitis and pneumococcal bacteremia over the years 2001–2004 per age [21]
Age Meningitis Bacteremia Pneumonia Otitis media
0–4 months 18 38 3400 103,067
5–11 months 45 48 3740 183,867
1 year 22 51 1960 155,200
2 years 6 31 3840 100,867
3 years 5 19 4740 114,600
4 years 4 9 3380 81,133
5 years 4 11 4020 71,667
6 years 2 6 2900 44,867
7 years 3 8 2580 27,067
8 years 2 4 1380 19,800









































































dlso shown are the average number of cases of clinical pneumonia and epi
ver the years 1996–2001 [19]. Pneumococcal meningitis, pneumococcal b
ere updated to adhere to the most recent version of the
utch guidelines on costing in pharmacoeconomic research
24]. Costs were measured in D using price levels of the year
004. The cost per dose of vaccination including adminis-
ration costs was assumed at D 50 (Personal communication
ith the Dutch Ministry of Health). Economic evaluation
as based on a cohort consisting of 193,789 infants born
n the Netherlands in 2004 with an average life expectancy
or newborns of 79 years (source: Central Bureau of Statis-
ics). For the threshold analysis on the vaccine cost per dose,
he only published – but still informal – Dutch threshold for
ost-effectiveness at D 20,000 per LYG or QALY [25] was
sed.
The model used by Bos et al. [17] was further extended by
he inclusion of an estimate of the effects of herd protection
sing the estimated decline in the incidence of IPD for all
erotypes in unvaccinated age groups published by Whitney
t al. [16] shown in Table 4.
Herd protection was assumed to affect only the number
f cases with invasive manifestations of pneumococcal dis-
ase (bacteremia, meningitis). Possible reductions in cases
f otitis media, pneumonia and meningitis sequelae were not
aken into account. We assumed the herd protection effects
or the duration of 1 year, to be consistent with the basis
f our analysis, i.e. one annual cohort of newborn infants.
he average number of cases of pneumococcal meningitis
nd pneumococcal bacteremia per year in the Netherlands
n these unvaccinated age groups is shown in Table 4. Of
hese cases, 50% of total bacteremia cases were assumed
o cause morbidity, whereas the other 50% was assumed
ot to be harmful in nature (Personal communication Dr.
. Spanjaard, Netherlands Reference Laboratory Meningi-
is, RIVM/AMC). The mortality rate for serious cases of
neumococcal bacteremia and meningitis among adults in
he Netherlands was assumed to be 25.9% [26] and 30.4%,
espectively [27]. Indirect costs due to mortality were cal-
ulated using the friction cost method with a friction period
f 154 days [24]. A vaccination schedule of four doses of
CV7 administered at the age of 2, 3, 4 and 12 months was




tf otitis media per year in the Netherlands (irrespective of causative agent)
ia and otitis media were corrected for underreporting.
months. Based on the results of Black et al. [13], efficacy
as assumed to be 85.7% at the ages of 5–11 months and
3.9% at the ages of 12 months to 9 years. Vaccine effec-
iveness was assumed to decline 3% per year starting 5 years
fter the last dosage [11]. Vaccine effectiveness against IPD
as calculated by multiplying the efficacy of the vaccine with
he serotype coverage (the proportion of IPD causing isolates
ith serotypes covered by the vaccine in the Netherlands [21]
or the age group 0–9 years). The effectiveness of the vaccine
gainst pneumonia and otitis media in children was assumed
o be 6% [28] and 6.4% [13], respectively (Tables 1–4).
.3. Web interface
This section describes the web interface that was used
o perform the scenario and sensitivity analyses. It can be
inked to health-economic models of various types (decision
nalytical, Markov, discrete event simulation) designed with
ommonly used software packages. Linking requires some
on-structural changes to the model. The web interface pro-
ides the user with an overview of relevant input parameters.
he values of the input parameters can be changed within
heir predefined constraints. The user can evaluate a prede-
ned or customized scenarios and is provided with a numeric
able of corresponding outcome parameters. Also, three
ypes of sensitivity analysis are available: univariate analysis,
ivariate analysis and multivariate (probabilistic) analysis.
esults of a univariate and bivariate sensitivity analysis
re presented in a two-dimensional line plot and three-
imensional surface plot, respectively (the default domain
s −25% to +25% of the base-case parameter values). In
he multivariate (probabilistic) analysis random values from
ser-specified distributions are drawn in a Monte Carlo sim-
lation [32–34]. An appropriate default distribution type is
pecified for each input parameter (normal, lognormal, stan-
ard beta, uniform, triangle or gamma distribution). If a
istribution type other than the default is selected, the user
hould be aware that not every distribution type is always
ppropriate. The distribution parameters are calculated from
he mean and standard error. Box 1 shows how the standard
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Table 2
Unit costs (in D ; price-levels: 2004), clinical and resource use parameters
Parameter description Value
Direct cost per case of uncomplicated meningitis or bacteremia [24] D 7,431
Direct cost per case of complicated meningitis [24] D 26,787
Mean direct cost of uncomplicated and complicated otitis media per episode [24] D 21
Direct cost per case of mild pneumonia [24] D 97
Direct cost per case of uncomplicated pneumonia [24] D 161
Direct cost per case of complicated pneumonia [24] D 3,232
Direct and indirect cost of lifetime hearing aids as sequelae of meningitis [29] D 4,909
Direct and indirect cost of lifetime care as sequelae of meningitis [30] D 1,004,238
Direct and indirect cost of special education as sequelae of meningitis [30] D 176,259
Indirect cost (loss of production by parents) per episode of otitis media [9] D 136
Indirect cost (loss of production by parents) per case of pneumonia [9] D 136
Indirect cost (loss of production by parents) average per case of meningitis or bacteremia [9] D 291
Direct cost per case of invasive infection [20,24] D 6,303
Indirect cost per case of invasive infection [20,24] D 2,364
Friction cost per case of invasive infection [24] D 14,958
Proportion of cases of pneumonia that are mild [19] 0.750
Proportion of cases of pneumonia that are uncomplicated [19] 0.126
Proportion of cases of pneumonia that are complicated [19] 0.124
Proportion of meningitis survivors with hearing impairments that require lifetime hearing aids [29] 1.000
Proportion of meningitis survivors with neurological sequelae that require to be institutionalized for life [30] 0.250
Proportion of meningitis survivors with neurological sequelae that require lifetime special education [30] 0.500
Proportion of cases of meningitis that are complicateda [17] 0.400
Proportion of adult bacteremia cases that are seriousa [17] 0.500
Proportion of cases pneumococcal meningitis with unilateral hearing impairment [31] 0.105
Proportion of cases pneumococcal meningitis with bilateral hearing impairment [31] 0.051
Proportion of cases pneumococcal meningitis with mental retardation [31] 0.042
Proportion of cases pneumococcal meningitis with spasticity [31] 0.035
Proportion of cases pneumococcal meningitis with epilepsy [31] 0.042
IPD, invasive pneumococcal disease.
a Bos et al. conducted a expert panel meeting in 1999 with representatives of the pediatric departments of most academic hospitals in the Netherlands.
Table 3
Estimated mean and standard error for parameters used in the multivariate probabilistic sensitivity analysis with the appropriate references
Parameter description Mean SE
Vaccine efficacy against IPD at age 4–11 months—partially vaccinated individualsa [13] 0.857 0.2551
Vaccine efficacy against IPD after age 12 months—fully vaccinated individualsa [13] 0.939 0.0482
The effectiveness of the vaccine against episodes of otitis media (all causative agents)a [13] 0.064 0.0122
The effectiveness of the vaccine against clinical pneumonia (all causative agents)a [28] 0.06 0.0242
Reduction in total cases of IPD in unvaccinated age-group 20–39a [16] 0.32 0.0408
Reduction in total cases of IPD in unvaccinated age-group 40–64a [16] 0.08 0.0357
Reduction in total cases of IPD in unvaccinated age-group 65 and oldera [16] 0.18 0.0332
Mortality of pneumococcal meningitis cases in children (population age mean 8 months)b [3] 0.169 0.0409
Mortality of pneumococcal bacteremia cases in children (population age < 15 years old)b [4] 0.06 0.0061
Mortality of pneumococcal meningitis cases in adultsb [27] 0.304 0.0245
Mortality of bacteremia cases in adultsb [26] 0.259 0.036
Serotype coverage of PCV7 of meningitis cases in the Netherlandsb [21] 0.671 0.025
Serotype coverage of PCV9 of meningitis cases in the Netherlandsb [21] 0.683 0.0247
Serotype coverage of PCV10 of meningitis cases in the Netherlandsb [21] 0.782 0.0219
Serotype coverage of PCV13 of meningitis cases in the Netherlandsb [21] 0.861 0.0184
Serotype coverage of PCV7 of bacteremia cases in the Netherlandsb [21] 0.595 0.0256
Serotype coverage of PCV9 of bacteremia cases in the Netherlandsb [21] 0.682 0.0243
Serotype coverage of PCV10 of bacteremia cases in the Netherlandsb [21] 0.78 0.0216
Serotype coverage of PCV13 of bacteremia cases in the Netherlandsb [21] 0.863 0.0179
For all parameters the standard beta distribution was used. IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine + number of serotypes
contained in vaccine; SE, standard error.
a The standard error was calculated from values published in literature using Eq. (1) (see Box 1).
b The standard error was calculated from values published in literature using Eq. (2) (see Box 1).
G.A.A. Hubben et al. / Vaccine
Table 4
Average number of cases per year in the Netherlands of meningitis and bac-
teremia in unvaccinated age-groups over the years 2001–2004, caused by all
serotypes of Streptococcus pneumoniae, corrected for underreporting [21]
and estimated percentage of decline in the incidence of invasive pneumo-
coccal disease for all serotypes in unvaccinated age groups according to
Whitney et al. [16]
Age Meningitis Bacteremia Decline incidence
IPD (95% CI)
20–39 years 25 251 32 (23–39)
40–64 years 89 756 8 (1–15)
≥65 years 79 1493 18 (11–24)
Box 1: Equations used to derive the stan-
dard error from data commonly found in
literature [32,34]
The distribution parameters are calculated by
method of moments estimation. This requires
an estimate of the mean and the standard error
(SE). In case a proportionwith a 95%conﬁdence
interval is available from the literature, the stan-
dard error can be approximated from the upper
(u) and lower (l) limit of the interval with Eq. (1),
assuming a normal distribution. If the data is
published in the formof r ‘successes’ fromn ‘tri-
als’, as is often the case for mortality, Eq. (2) can
be used to estimate the probability (pˆ, assumed
as the mean) by maximum likelihood estima-
tion and calculate the standard error, assuming
a binomial sampling distribution [32].
SE ≈ u − l








































Brief description of the seven alternative scenarios
Scenario Description
No herd A scenario assuming that no herd protection will
3-doses A scenario exploring the effects of a 3-doses inste
only affects the investment costs. It is assumed th
Low discount rate effects A scenario applying a 1.5% instead of a 4% disco
pharmacoeconomic research, to discount both co
health effects [24].
PCV9a Application of PCV9, a 9-valent vaccine that is c
addition to the serotypes 4, 6B, 9V, 14, 18C, 19F,
PCV10a Application of PCV10, a 10-valent vaccine that is
9-valent vaccine and 19A.
PCV13a Application of PCV13, a 13-valent vaccine that is
10-valent vaccine and 3, 6A and 7F.
Effectiveness 5 years A scenario that assumes the vaccine effectiveness
a A change in the number of serotypes affects the serotype coverage used to cal
involves the same vaccine effectiveness as the base-case analysis.25 (2007) 3669–3678 3673
rror can be derived from data commonly published in liter-
ture. The results of a multivariate probabilistic sensitivity
nalysis are presented in a two-dimensional graph show-
ng the acceptability curve and uncertainty interval for each
elected outcome parameter. Optionally, a scatter plot can
e generated showing the cost-effectiveness plane. Both esti-
ates for the mean and median iCER are plotted in the graph.
f possible, a 95% uncertainty interval is estimated and graph-
cally shown by taking the 2.5 and 97.5 percentiles from the
onte Carlo simulations.
.4. Scenario and sensitivity analysis
In addition to the base-case analysis, seven additional sce-
arios evaluating the impact of herd protection, the number
f doses, the discount rate for effects, the number of serotypes
n the vaccine and the duration of vaccine efficacy are pre-
ented. These scenarios are equal to the base-case scenario
ith the exception of the characteristics described in Table 5.
nivariate sensitivity analysis was performed for the vaccine
ost per dose and bivariate sensitivity analysis on the dis-
ount rate for costs and for effects. Multivariate probabilistic
ensitivity analysis of second order uncertainty (1000 runs
f Monte Carlo simulation) was performed using standard
eta distributions [32]. Only parameters representing natural
henomena (efficacy, effectiveness, mortality, vaccine cov-
rage and herd protection) were included in the multivariate
nalysis. Other parameters, such as unit costs were assumed
o have a fixed value. All results and graphs presented in the
esults section were generated using the web interface.
. Results
.1. Base-caseIn the base-case analysis the investment costs of the vacci-
ation program would amount toD 38,757,800, while it would
revent a total number of 78 deaths and 44 lifetime seque-
occur.
ad of a 4-doses schedule. A change in the number of doses administered
at this a scenario involves the same efficacy as the base-case analysis [15].
unt rate for health effects. It was anticipated that the Dutch guideline for
st and health effects at 4%, might be changed to 4% for costs and 1.5% for
urrently under development by Wyeth, containing serotypes 1 and 5 in
23F contained in the 7-valent vaccine.
currently under development by GSK and containing the serotypes of the
currently under development by Wyeth, containing serotypes of the
lasts up to and including the age of 5 years.
culate vaccine effectiveness against IPD. It is assumed that this scenarios
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Table 6
Health effects in the base-case analysis: discounted quality adjusted life years
gained (QALYs), discounted life years gained (LYGs) and undiscounted
cases averted for the vaccinated cohort, unvaccinated age groups and total
Life years Vaccinees Unvaccinated Total
QALYs gained 529 868 1,397
LYGs 385 868 1,253
Cases averted Vaccinees Unvaccinated Total
Meningitis 55 29 84
Bacteremia 103 205 308
Pneumonia 1, 795 1, 795
Otitis media 52, 407 52, 407
Lifetime sequelae 44 44
Death 16 62 78
Table 7
Cost averted (savings) in the base-case analysis (in D ; price-levels: 2004)
for the vaccinated cohort, unvaccinated age groups, and total
Direct costs averted Vaccinees Unvaccinated Total
IPD 1,504,500 1,475,700 2,980,200
Non-invasive 1,998,000 1,998,000
Sequelae meningitis 6,077,600 6,077,600
Total 9,580,100 1,475,700 11,055,800
Indirect costs averted Vaccinees Unvaccinated Total
IPD 43,100 553,500 596,600
























iCER per QALY 14,000
iCER per LYG 15,600









selected for sensitivity analysis that are presented here show












Eotal 6,693,700 1,480,400 8,174,100
ae, resulting in a total of 1397 discounted QALYs gained or
253 discounted LYG. Averted direct and indirect costs (sav-
ngs) would be D 11,055,800 and D 8,174,100, respectively.
n the base-case analysis, the net costs of the program would
herefore be D 19,527,900, resulting in an iCER of the vacci-
ation program at D 14,000 per QALY or D 15,600 per LYG.
he cost-effectiveness threshold analysis estimated a vaccine
ost per dose of D 60.85. The detailed financial benefits and
ealth effects of the vaccination program are presented in
ables 6 and 7. Results for the vaccinated cohort, unvacci-
ated age groups and totals are shown separately. In Table 8




ean incremental cost-effectiveness ratios (iCERs) per quality adjusted life year (
UI) derived from scatter plots for the base-case analysis and seven alternative scen
cenario iCER per QALY
ase-case 14,000 (9,800–20
o herd 42,600 (31,300–7
-doses 7,000 (4,100–11




ffectiveness 5 years 15,800 (11,500–2raph 1. Univariate sensitivity analysis showing the effect on the iCER per
ALY of varying the vaccine cost per dose from D 30 to D 70 (all other
arameters as in the base-case analysis).
.2. Scenario- and sensitivity analysis
The results of the base-case and scenario analyses are pre-
ented in Table 9. Shown is the mean iCER per QALY and
ean iCER per LYG, with their 95% uncertainty intervals
stimated by multivariate probabilistic sensitivity analysis.
The results of the sensitivity analysis for the base-case
nalysis are presented in Graphs 1–4. The input parametershe effect on the iCER per QALY of varying the vaccine
ost per dose from D 30–D 70. A bivariate sensitivity analysis
QALY) gained and life year gained (LYG) with 95% uncertainty intervals
arios (in D ; price levels: 2004)


































Graph 4. Results of the Monte Carlo simulation for the base-case analysis,
presented as a scatter plot of the cost-effectiveness plane with 95% UI. This
graph shows the health effects (here: QALYs gained) on the x-axis and the






iraph 2. Bivariate sensitivity analysis showing the effect on the iCER per
ALY of varying the discount rates for both costs and effects from 1.5% to
% (all other parameters as in the base-case analysis).
s depicted in Graph 2, showing the effect on the iCER per
ALY of varying the discount rates for costs and effects from
.5% to 4%. The results of the multivariate probabilistic sen-
itivity analysis are displayed as an acceptability curve and
s a scatter plot in Graphs 3 and 4, respectively. In Graph
, the horizontal 2.5, 50 and 97.5 percentile lines are plotted
epresenting the (rounded) median iCER of D 14,000 with
95% uncertainty interval of D 9,900–20,200 per QALY. In
raph 4, the results are displayed as a scatter plot of the
ost-effectiveness plane, with the health effects (here: QALYs
ained) on the x-axis and the financial effects (net costs) on
he y-axis. As explained above, further sensitivity analysis
an be performed by the reader using the web interface of the
odel.
raph 3. Results of the Monte Carlo simulation for the base-case analysis,
resented as an acceptability curve of the iCER per QALY. Indicated are the
orizontal 2.5, 50 and 97.5 percentile lines representing with corresponding
ertical lines to the intercept values on the x-axis, representing a (rounded)
edian iCER of D 14,000 with a 95% UI of D 9,900–20,200 per QALY. A
illingness to pay of D 20,000 per QALY for the Netherlands corresponds


























bines drawn, representing the UI lower bound, median and UI upper bound,
espectively. Also drawn is the line representing the mean that in this case
pproximately coincides with the median.
. Discussion
.1. Study results
In 2001, the Dutch Ministry of Health decided not to
nclude PCV7 in the NVP. This decision was based among
ther data on the conclusion from the results of the study
y Bos et al. [17], that the cost-effectiveness ratio for inclu-
ion of PCV7 in the NVP was unfavorable. Recent data on
erd protection effects and a reduced dosage regimen have
enewed the debate on inclusion of PCV7 in the NVP. Even
ith a slightly higher cost per dose of vaccination than pre-
iously analyzed, the results of our new study show a more
avorable iCER of D 14,000 per QALY or D 15,600 per LYG
ompared to the previous estimates by Bos et al. of D 71,250
er QALY or D 82,700 per LYG. This difference can be
argely attributed to the herd protection effects, as is illus-
rated by the iCER of D 42,600 per QALY of scenario ‘No
erd’, where herd protection effects are excluded. A smaller
ontribution to the lower iCER estimated in our study can be
ttributed to the use of vaccine coverages of PCV7 of 0.671
nd 0.595 for pneumococcal meningitis and pneumococcal
acteremia, respectively, derived from more recent data [21].
cenario ‘No Herd’, using a vaccine coverage of 0.58 and
.52 as applied by Bos et al., results in an iCER of D 51,200
er QALY. Also some difference is caused by various recent
hanges in the guidelines for costing in pharmacoeconomic
esearch in the Netherlands [24]. In particular, the guideline
osts of an inpatient day and those of production losses have
ncreased significantly. Another factor of lesser importance is
he use of different base years for costing (2001 versus 2004).
Ideally herd protection effects of PCV7 vaccination should
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ently data on the transmission dynamics of Streptococcus
neumonia is only limited. To estimate the herd protection
ffects, data on the reduction of IPD in unvaccinated age
roups in California have now been used. One important
spect in the occurrence of herd protection involves the con-
act patterns between age groups that could differ between the
S and the Netherlands. Also, the herd protection effects did
ot include a decline in cases of otitis media and pneumonia
n unvaccinated age groups due to unavailability of data. It
s likely that this causes an underestimation of the beneficial
ealth effects of the vaccine. Additionally, in our analysis it
as assumed that serotype replacement is absent. However,
ecent evidence suggests that some serotype replacement may
ccur, implying that the beneficial health effects of the vac-
ine might be overestimated in our analysis. No data was
vailable to estimate this effect, but at this moment we do not
xpect serotype-replacement to have a large impact on the
stimated cost-effectiveness ratios [35].
Not surprisingly, the univariate sensitivity analysis shows
hat the iCER is highly sensitive for the vaccine cost per
ose. The bivariate sensitivity analysis on discount rates very
learly illustrates that the iCER of the vaccination program
s much more sensitive to the discount rate for effects than
he rate for costs. This is a general phenomenon for eco-
omic evaluations of infant vaccination programs, and often
or any preventive program [36]. The results of the probabilis-
ic sensitivity analysis, as shown in Graph 3, indicate that at
willingness to pay of 20,000 per QALY for the Netherlands
25] the inclusion of PCV7 in the NVP of the Netherlands
an be considered cost effective with a high probability.
.2. Web interface
To enhance the transparency of economic evaluation
nd provide the decision maker with an instrument to
nsure a minimum quality of such analyses, guidelines
or pharmacoeconomic research have been formulated
or a growing number of countries (http://www.ispor.org/
Eguidelines/index.asp). These guidelines include recom-
endations on good modeling practice, including for
xample checks to ensure internal and external validity, trans-
arency and study design. Any evaluation of a vaccine should
dhere to these general guidelines for health economics [37].
s such, these guidelines – and adherence to it – in combi-
ation with peer-reviewed publication of the model, should
uarantee a minimum level of quality allowing the decision
aker to base a decision on the (published) results.
However, these guidelines do not address all specific prob-
ems remaining in economic evaluation of (new) vaccines.
n this study we focus on the limitations of the flexibility
nd transparency inherent in the manner economic evalua-
ions are published. On flexibility, firstly, we note that after
ublication additional information from (observational) stud-
es may become available, e.g. on effectiveness and serotype
overage of the vaccine of interest. As this type of economic





odel parameters are primarily based on the results of a lim-
ted number of trials, some of which might be still ongoing.
herefore, the evidence available at the time of submission
s likely to change.
Secondly, the decision maker’s demand for information
ay change over time and although the model on which
n evaluation was based may still be relevant, the published
esults alone may not suffice. The decision maker may require
pdates of the published analyses or additional scenarios to
e investigated that may address various what-if scenarios
o better appreciate all political factors involved. Given the
otential difference in interests and sub-optimal communica-
ion between decision makers and researchers, it is unrealistic
o expect that the author(s) can anticipate all relevant scenar-
os. Moreover, published scenario- and sensitivity analyses
re limited by the obvious practical constraints of a jour-
al and the choices made by the author(s). In addition, it is
ot practical nor accepted by journals to publish updates of
valuations over short intervals of time whenever the decision
aker’s information need changes, or new evidence becomes
vailable.
An important issue regarding transparency is that decision
akers often perceive economic studies as incomprehensi-
le ‘black boxes’, because the model is not fully published
nd usually not integrally part of the peer-review process. By
roviding more clarity as recommended by Beutels [38], a
eb interface might help to remove this bias to some extent.
y performing sensitivity analysis on the model the user is
rovided with additional understanding of the limitations of
he model, while information about the uncertainty of the
odel parameters is obtained by observing the impact of
hanges in model parameters. Also, the ability to perform
ensitivity and scenario analysis on all relevant model param-
ters facilitates the assessment of international transferability
nd may help adaptation of the study design to other geo-
raphical areas if desired [39]. Users can study the model
ehavior in more detail, test its robustness and adapt the
odel to their local conditions to assess its validity. Interac-
ion with the economic model through a web interface might
lso allow a more thorough peer-review of the model prior to
ublication.
Ideally, the decision maker or user should be able to “play
round” with a user-friendly and validated model to compare
ifferent conditions of vaccine application and payment. We
elieve that the usability of economic evaluations of vaccines
ould be improved by making the models of economic evalua-
ions available on the Internet, parallel with the peer-reviewed
ublication in the scientific literature.
One of the limitations of the interactive model is that it
oes not allow the user to adjust the model to allow for
ffects that require structural changes. Also, the number of
uns in the Monte Carlo simulation used in multivariate sen-
itivity analysis is limited to 1000 to reduce the load on the
erver. In addition, extending the user interface with options
or advanced sensitivity analysis increases complexity that
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. Conclusions
We have demonstrated the application of a web interface
o allow interaction with a cost-effectiveness model for
CV7. We have suggested the potential benefits of making
odels of economic evaluations available in this way parallel
ith a publication in a journal, to enhance decision support
nd improve flexibility and transparency. Our approach
as exemplified with a model projecting the impact of
ation-wide infant vaccination with PCV7 in the Nether-
ands. For this analysis, the iCER per QALY, estimated by
ur analysis of the base-case scenario, is 14,000 (95% UI:
,800–20,200). At a willingness to pay of 20,000 per QALY
or the Netherlands [25] the PCV7 vaccination program can
e considered cost effective with a high probability. The
ubstantial difference with the base-case iCER per QALY of
1,250 reported by Bos et al. [17] can for the greater part be
ttributed to the inclusion of the effects of herd protection
n the model. To our knowledge, this is the first economic
valuation of a vaccination program that describes the use
f a web interface to bridge the gap between analyst and
ecision maker. The usefulness of this approach will have to
e confirmed by use in practice.
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